# COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

> **NCT05289037** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1270 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** AS03
- **BIOLOGICAL:** BNT162b2
- **BIOLOGICAL:** BNT162b2 (B.1.1.529)
- **BIOLOGICAL:** BNT162b2 (B.1.351)
- **BIOLOGICAL:** BNT162b2 bivalent (wildtype and Omicron BA.1)
- **BIOLOGICAL:** BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)
- **BIOLOGICAL:** CoV2 preS dTM [B.1.351]
- **BIOLOGICAL:** CoV2 preS dTM/D614
- **BIOLOGICAL:** CoV2 preS dTM/D614+B.1.351
- **BIOLOGICAL:** mRNA-1273
- **BIOLOGICAL:** mRNA-1273.351
- **BIOLOGICAL:** mRNA-1273.529
- **BIOLOGICAL:** mRNA-1273.617.2
- **OTHER:** Sodium Chloride, 0.9%

## Key facts

- **NCT ID:** NCT05289037
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-30
- **Primary completion:** 2023-11-22
- **Final completion:** 2023-11-27
- **Target enrollment:** 1270 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05289037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05289037, "COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05289037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*